MOTS-c Before and After: New Insights Into Metabolic Health

MOTS-c is a tiny peptide, just 16 amino acids long, encoded within the mitochondrial genome, and it has rapidly become one of the most studied molecules in metabolic health research since its discovery in 2015. What makes it compelling from a “before and after” perspective is that its levels shift measurably in response to exercise, metabolic stress, and aging, and that administering it to animals changes markers of metabolic disease in ways researchers find striking. The story is far from complete, with conflicting human data on baseline levels and no approved clinical applications, but the breadth of systems MOTS-c touches makes it worth understanding.

A Peptide That Comes From Mitochondria

Most of the proteins your body uses are encoded by the DNA in the cell nucleus. MOTS-c is different. It is encoded by a short stretch within the mitochondrial 12S ribosomal RNA gene, making it one of a small family of “mitochondrial-derived peptides” that includes humanin and a handful of others.¹ The existence of these peptides was itself a surprise; for decades, scientists thought mitochondrial DNA only coded for 13 proteins involved in energy production and some structural RNA. Discovering that mitochondria also produce signaling molecules that influence the rest of the cell reshaped how researchers think about these organelles.²

What separates MOTS-c from a typical mitochondrial product is where it ends up. Under metabolic stress or during exercise, MOTS-c moves from the cytoplasm into the cell nucleus, where it can directly influence which genes get turned on or off. That nuclear translocation depends on an energy-sensing enzyme called AMPK, the same master switch that activates during calorie restriction and intense physical activity.³ Once in the nucleus, MOTS-c helps switch on genes involved in stress adaptation, particularly those with antioxidant response elements.⁴ Recent work has started mapping the physical machinery that ferries MOTS-c into the nucleus, identifying a motor protein called MYH9 as part of the transport system.⁵

The AMPK Connection and Why It Matters

The primary metabolic action of MOTS-c traces through a specific biochemical route. It inhibits part of the folate cycle, which is intertwined with the production of building blocks for DNA. That inhibition causes a molecule called AICAR to accumulate, and AICAR is a natural activator of AMPK.⁶ AMPK is sometimes called the cell’s fuel gauge: when energy is low, AMPK flips on processes that generate fuel (like burning fat) and turns down processes that consume it (like building new fat stores). By activating AMPK, MOTS-c mimics some of the cellular effects of exercise and calorie restriction, and skeletal muscle appears to be its primary target tissue.⁷

This is a useful framing for understanding almost everything else researchers have observed about MOTS-c. Many of the “after” improvements in animal studies, from better blood sugar control to reduced fat accumulation, track back to this AMPK-driven cascade.

How Exercise Changes MOTS-c Levels

The clearest “before and after” data in humans comes from exercise studies. When young men performed a single session of intense cycling, MOTS-c levels in skeletal muscle jumped roughly 12-fold. Circulating levels in the blood rose about 1.5- to 1.6-fold during and immediately after the bout. Both measures returned toward baseline after a few hours of rest.⁸ This spike-and-return pattern looks a lot like what happens with other exercise-responsive hormones, suggesting MOTS-c acts as an acute signal rather than a slowly building reservoir.

The picture gets murkier when you look at long-term training. Some studies found that weeks of endurance exercise raised resting MOTS-c levels, including in older men with prediabetes and in breast cancer survivors after a combined endurance-and-resistance program. Others, including a two-week cycling protocol in young men and an eight-week endurance program in women with polycystic ovary syndrome, found no lasting change.⁹ The type, duration, and intensity of exercise all seem to matter, and so does the population studied. One intriguing finding is that professional endurance athletes actually have lower resting MOTS-c levels than non-athletes, with a dose-dependent drop as endurance capacity increases.¹⁰ That paradox may reflect the body adapting so that less of the signal molecule is needed at rest once the metabolic machinery is well-tuned, but this is speculative.

The Confusion Around Obesity and Diabetes Baselines

If you are hoping for a simple story where “metabolically unhealthy people have low MOTS-c and healthy people have high levels,” the data will frustrate you. Three separate human studies measured circulating MOTS-c in lean versus obese individuals and reached different conclusions. One found that plasma MOTS-c was essentially the same in both groups (around 0.5 ng/mL), though it correlated with insulin sensitivity in lean subjects only.¹¹ A second found that circulating levels were significantly higher in people with obesity (about 264 pg/mL) than in lean controls (about 213 pg/mL), and that the levels did not budge after weight loss.¹² A third found no significant difference at all between the groups.¹³

These discrepancies probably reflect real methodological differences: the assays used to measure MOTS-c vary, the populations differed in ethnicity and metabolic severity, and sample sizes were small. They also highlight a bigger issue. Circulating levels of a peptide do not necessarily reflect what is happening inside cells or tissues. MOTS-c may be produced, used, and cleared locally in skeletal muscle or fat without those changes showing up reliably in a blood draw. For now, treating blood MOTS-c as a straightforward biomarker of metabolic health is premature.

Fat, Liver, and Whole-Body Energy Use

Animal experiments paint a more consistent picture. When MOTS-c is administered to mice, it increases the activity of brown fat, the type of fat tissue that burns calories to generate heat. It also promotes the “browning” of ordinary white fat, meaning white fat cells start behaving more like brown fat and burning energy instead of storing it.¹⁴ The practical effect is that treated mice produce more body heat and gain less fat on high-calorie diets. Researchers noted that these metabolic benefits came from changes in how the body used energy, not from the animals eating less or moving more.¹⁵

The liver is another organ where before-and-after effects are dramatic in mice. Nonalcoholic steatohepatitis, or NASH, involves progressive fat buildup, inflammation, cell death, and scarring in the liver. In a mouse model of NASH, both preventive (long-term) and therapeutic (short-term) courses of MOTS-c treatment reduced liver fat accumulation, inflammation, cell death, and fibrosis.¹⁶ Given that NASH is one of the fastest-growing liver diseases worldwide and lacks satisfying drug therapies, these preclinical results have generated excitement, though mouse liver results have a notoriously poor track record of translating directly to humans.

Protecting Muscle as You Age

Age-related muscle loss, or sarcopenia, is driven partly by chronic low-grade inflammation and insulin resistance, both of which increase signals that tell muscle to break itself down. One of the key “self-destruct” signals is myostatin, a protein that suppresses muscle growth. In mice fed a high-fat diet, MOTS-c administration lowered circulating myostatin levels. Lab experiments in muscle cells showed the mechanism: MOTS-c boosts a pro-growth pathway (through AKT) while suppressing a transcription factor called FOXO1 that would otherwise turn on myostatin and other muscle-wasting genes.¹⁷

In older mice, injecting MOTS-c improved physical performance on running and grip-strength tests, even when treatment started late in life.⁸ The combination of AMPK activation (which promotes muscle energy metabolism) and myostatin suppression (which blocks muscle wasting) gives MOTS-c a two-pronged action that few single molecules offer. Whether these effects translate to meaningful gains in human muscle mass or function remains untested in clinical trials.

Bone Remodeling and Osteoporosis

Bone is constantly being torn down by osteoclasts and rebuilt by osteoblasts. When that balance tips toward breakdown, osteoporosis follows. MOTS-c appears to push the balance toward building. Studies show it promotes the proliferation and maturation of osteoblasts (the bone-building cells) while inhibiting osteoclast formation (the bone-destroying cells).¹⁸ In cell culture, MOTS-c steered bone marrow stem cells toward becoming osteoblasts rather than fat cells, working through a signaling pathway involved in tissue growth and repair.¹⁹ This is relevant because aging shifts that same stem-cell decision in the opposite direction: more fat, less bone. If MOTS-c can reverse or slow that shift, it might address sarcopenia and osteoporosis simultaneously, since both conditions share overlapping risk factors and often coexist in older adults.

Brain Injury and Cognitive Decline

A newer area of MOTS-c research involves the brain. In mouse models of traumatic brain injury, MOTS-c treatment improved movement, balance, and spatial memory compared with untreated animals.²⁰ In sepsis-related brain injury, MOTS-c decreased inflammation, reduced damage to the blood-brain barrier, and increased production of neurotrophic factors, the proteins that support nerve cell survival.²¹

Perhaps most intriguing for age-related disease, a modified version of MOTS-c that can cross the blood-brain barrier enhanced memory formation in healthy mice and reversed memory deficits caused by amyloid-beta, the protein fragment central to Alzheimer’s disease pathology. The mechanism appeared to involve calming overactive immune cells in the brain (astrocytes and microglia) and reducing the inflammatory molecules they produce.²² These are early-stage animal results, but they extend the MOTS-c story well beyond metabolism into neurodegenerative territory.

A Longevity Link in Centenarians

One of the reasons MOTS-c attracts attention beyond its metabolic effects is a genetic observation in exceptionally long-lived people. Researchers studying Asian centenarians found that these individuals were more likely to carry a particular variant within the stretch of mitochondrial DNA that encodes MOTS-c, suggesting that the version of MOTS-c a person produces could influence lifespan.²³ This does not prove that MOTS-c drives longevity on its own; mitochondrial DNA variants are inherited as a package, so the variant could be a marker for a broader mitochondrial profile. Still, combined with the animal data showing improvements in insulin sensitivity, muscle function, and stress resilience, the finding fits a pattern where MOTS-c influences several processes that deteriorate with age.

Cancer and Tumor Metabolism

Cancer cells rewire their metabolism to fuel rapid growth, and recent work has explored whether MOTS-c intersects with that rewiring. In ovarian cancer, MOTS-c levels were found to be reduced in both the blood and tumor tissue of patients, and lower levels tracked with worse outcomes. When researchers supplied MOTS-c to ovarian cancer cells in the lab, it slowed proliferation, blocked migration and invasion, triggered cell-cycle arrest, and promoted cell death. The mechanism involved MOTS-c binding to an enzyme called LARS1 and tagging it for destruction, effectively cutting off a support system the cancer cells relied on.²⁴ This is a single cancer type studied largely in cells and animal models, so it would be a stretch to call MOTS-c an anti-cancer therapy. But it illustrates how broadly the peptide’s signaling network reaches.

Why There Are No Human Therapies Yet

Given all the promising animal data, a reasonable question is why MOTS-c is not already in clinical trials for diabetes, sarcopenia, or NASH. Several practical hurdles stand in the way. MOTS-c is a small peptide, and small peptides are notoriously fragile in the bloodstream. Researchers developing detection methods for anti-doping purposes have had to carefully characterize its stability and breakdown products, underscoring just how quickly the body can chew it up.²⁵ Delivering a therapeutic dose that survives long enough to reach skeletal muscle, liver, or brain in meaningful concentrations is a formidable challenge. The modified version used in the Alzheimer’s mouse study, for example, had to be specifically re-engineered to cross the blood-brain barrier.

There is also the measurement problem described earlier. Without a reliable, standardized blood assay, it is difficult to run the kind of dose-finding studies a clinical trial requires. Different labs using different kits report MOTS-c concentrations that differ by orders of magnitude, making cross-study comparisons unreliable. Until these technical issues are resolved, human trials will be hard to design well.

Meanwhile, MOTS-c peptide is already sold by supplement and peptide vendors marketing it for fat loss, anti-aging, and exercise performance. These products exist in a regulatory gray zone and come with no clinical evidence of efficacy or safety in humans. The anti-doping community is watching closely enough to develop detection assays, which tells you that at least some athletes are using or considering it, but “detectable in blood” and “proven safe and effective” are very different bars.

What Exercise Already Does to Your Own MOTS-c

If you are looking for the most actionable takeaway from the MOTS-c research so far, it is this: the interventions proven to raise MOTS-c levels in muscle and blood are already things physicians recommend for metabolic health. A hard exercise session can spike skeletal muscle MOTS-c by an order of magnitude.⁸ That transient surge appears to be part of how exercise delivers its metabolic benefits, working synergistically with other AMPK-activating signals to improve insulin sensitivity and glucose handling.⁷ In a sense, every time you finish a vigorous workout, you are running your own “before and after” experiment with MOTS-c, even if you never measure it. The research into exogenous MOTS-c is essentially trying to bottle that effect for people who cannot exercise or whose endogenous production has declined with age, and that goal remains firmly in the future.